NCT07238647

A Trial of HRS-5817 in Obese Participants

A Phase I, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Subcutaneous Administration of Single Ascending Doses of HRS-5817 in Obese Participants

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Atridia Pty Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	HRS-5817	Single dose of HRS-5817/placebo given subcutaneously (dose level 1 )
DRUG	HRS-5817	Single dose of HRS-5817/placebo given subcutaneously (dose level 2 )
DRUG	HRS-5817	Single dose of HRS-5817/placebo given subcutaneously (dose level 3 )
DRUG	HRS-5817	Single dose of HRS-5817/placebo given subcutaneously (dose level 4)

Timeline

• Start date: 2026-01-05
• Primary completion: 2027-01-30
• Completion: 2027-01-30
• First posted: 2025-11-20
• Last updated: 2026-01-16

Locations

1 site across 1 country: Australia